Navigation Links
Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information

Rockville, MD (PRWEB) January 14, 2014

Global Record Systems, LLC, (GRS), a company dedicated to developing innovative information technology solutions for patients, physicians, the biopharmaceutical industry, regulators, payers, and other health care stakeholders, announced today the signing of a three-year Research Collaboration Agreement (RCA) with the US Food and Drug Administration (FDA). This initiative is designed to generate disruptive solutions to challenges related to patient safety, clinical outcomes, and medication adherence.

It is estimated that 2 million Americans are harmed each year by various drug safety issues that result in as many as 100,000 deaths annually. Further, most current Risk Evaluation and Mitigation Strategies (REMS) are predicated on the passive reporting of adverse events by physicians and biopharmaceutical companies. Given this current approach, it is estimated that only 10% of actual important adverse events are reported to the FDA. The GRS’ EHDI proposes to address these issues by interacting directly with patients and, with patient consent, leveraging the health care information stored in Electronic Medical Records (EMRs).

Global Record Systems is providing a cloud-based digital health platform to collect patient-centered data on a near real-time basis. The FDA will provide GRS with clinical research questions to inform the data collection and analysis. FDA will not provide access to any confidential data. GRS’ EHDI will collect responses using patient-centered digital technologies including voice recognition software, EMRs, Smart Phones and Tablets at the point of care in doctors’ offices, retail pharmacies, and patient homes. The purpose of these queries and subsequent data analyses is to accumulate primary information in the “voice-of-the-patient” to improve patient safety and critical clinical outcomes. It is projected that the EHDI will collect approximately 100 million patient records over the next 3-4 years thus creating the largest database of its kind in the world. Through this system, it is anticipated that coded data from EMRs, global clinical trials, patient safety, clinical outcomes, and medication adherence will be collected and archived. FDA will be able to query the database to identify relevant clinical research information regarding public health benefits of medications.

Sandra Garrett, PhD, CEO of Global Record Systems said, “We envision this collaboration with the FDA as a new paradigm in the assessment of drug safety, clinical outcomes and medication adherence. By integrating longitudinal patient care and clinical outcomes data into a usable output that incorporates the “voice-of-the-patient” (the ultimate end-user of the healthcare system) in the EHDI, we anticipate an improved ability to track evolving patterns of medication safety and use. It is anticipated that the EHDI would provide regulators with the ability to track safety, efficacy, and outcomes in patients across a wide array of disease states. The net result would be important data that would be supplemental to traditional pre- and post-approval outcomes information (especially cardiovascular), REMS, or Registry programs while offering critical analyses of comparative effectiveness. Ultimately, such data could lead to better utilization of financial resources and better medical information directed at improving population health management.”

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
2. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
3. Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List
4. StemCyte Adds World Class Talent to its North America and Global Operations
5. Sequenom Named to NASDAQ Global Select Market
6. Synthetic Biology: Emerging Global Markets
7. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
8. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
9. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
10. MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016
11. Accuray Surpasses 600 Installations Globally
Post Your Comments:
(Date:6/27/2016)... ... 2016 , ... Newly created 4Sight Medical Solutions ... healthcare market. The company's primary focus is on new product introductions, to include ... are necessary to help companies efficiently bring their products to market. , The ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
Breaking Biology News(10 mins):